301 related articles for article (PubMed ID: 23995076)
1. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.
Mulaku M; Opiyo N; Karumbi J; Kitonyi G; Thoithi G; English M
Arch Dis Child; 2013 Nov; 98(11):908-14. PubMed ID: 23995076
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
5. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
7. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
Rees AL
J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
[TBL] [Abstract][Full Text] [Related]
9. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
Lanzkron S; Strouse JJ; Wilson R; Beach MC; Haywood C; Park H; Witkop C; Bass EB; Segal JB
Ann Intern Med; 2008 Jun; 148(12):939-55. PubMed ID: 18458272
[TBL] [Abstract][Full Text] [Related]
10. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L
J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903
[TBL] [Abstract][Full Text] [Related]
11. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
13. Hydroxycarbamide for sickle-cell anaemia in infancy.
Weatherall DJ
Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
[No Abstract] [Full Text] [Related]
14. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
17. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
[TBL] [Abstract][Full Text] [Related]
18. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
19. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
20. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
Jayabose S; Tugal O; Sandoval C; Patel P; Puder D; Lin T; Visintainer P
J Pediatr; 1996 Oct; 129(4):559-65. PubMed ID: 8859263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
